Eli Lilly (LLY) has had a stellar run with its Q2 2024 earnings, outperforming expectations. The firm raised its full-year revenue guidance by $3 billion due to impressive sales of Mounjaro and Zepbound. These sales helped fuel a beat-and-raise quarter, causing the stock to surge. Eli Lilly also made strategic position adjustments according to PRIMECAP Management's Q2 overview. This company is now a top pick at Morgan Stanley and many hedge funds. Stock price predictions for 2025-2030 look promising. There's some concern about a potential supply shortage, but LLY's stock keeps climbing. Its stock was noted for rapidly increasing, especially after bolstering their guidance. Zepbound and Mounjaro were pivotal in the earnings beat and guidance boost. LLY has been hailed as 'The Next $1 Trillion Market Cap Stock'. Approval of Zepbound in China caused the stock to soar even higher. The success of Lilly's Tirzepatide in a phase 3 study, showing benefits in adults with heart failure and obesity, was particularly impressive. The company also revealed plans to acquire Morphic to improve outcomes for patients with inflammatory bowel disease.
Eli Lilly LLY News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Sun, 11 Aug 2024 23:45:06 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 2
